Novo Nordisk raises 2026 outlook as Wegovy pill sales reach 5.4 billion kroner
Novo Nordisk raises 2026 outlook as Wegovy pill sales reach 5.4 billion kroner
Updated at: November 5, 2026 at 01:18 AM
Novo Nordisk raised its 2026 outlook on November 4 after stronger sales of its obesity treatments. The Danish drugmaker now expects adjusted sales and adjusted operating profit each to change by between minus 2 and plus 2 percent at constant exchange rates over the full year.
Third-quarter sales reached 79.195 billion Danish kroner, up 4 percent at constant exchange rates. The company said demand for GLP-1 products increased across both its US and international businesses, particularly in obesity care.
The Wegovy pill generated 5.394 billion kroner during the quarter. By the end of September it had launched in the United States, United Arab Emirates, Britain and Germany. Four more launches subsequently brought the number of markets to eight.
Adjusted operating profit rose 27 percent to 31.720 billion kroner at constant exchange rates. The comparison benefited from 9 billion kroner of transformation costs recorded a year earlier, which had lowered the previous yearβs base.
Reported operating profit moved in the opposite direction, falling 9 percent on the same exchange-rate basis. It included 8.7 billion kroner in non-cash impairment charges related to a drug project and changes to the manufacturing network.
Chief executive Mike Doustdar said the company was preparing for a US launch of CagriSema in early 2027, subject to regulatory approval. Broader access to medicines and continued international launches remain part of its plans.
